KR102465067B1 - 진핵 게놈 변형을 위한 조작된 cas9 시스템 - Google Patents

진핵 게놈 변형을 위한 조작된 cas9 시스템 Download PDF

Info

Publication number
KR102465067B1
KR102465067B1 KR1020207026571A KR20207026571A KR102465067B1 KR 102465067 B1 KR102465067 B1 KR 102465067B1 KR 1020207026571 A KR1020207026571 A KR 1020207026571A KR 20207026571 A KR20207026571 A KR 20207026571A KR 102465067 B1 KR102465067 B1 KR 102465067B1
Authority
KR
South Korea
Prior art keywords
leu
lys
arg
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207026571A
Other languages
English (en)
Korean (ko)
Other versions
KR20200121342A (ko
Inventor
티모시 시벡
푸치앙 첸
그레고리 데이비스
Original Assignee
시그마-알드리치 컴퍼니., 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마-알드리치 컴퍼니., 엘엘씨 filed Critical 시그마-알드리치 컴퍼니., 엘엘씨
Priority to KR1020227002190A priority Critical patent/KR102494449B1/ko
Publication of KR20200121342A publication Critical patent/KR20200121342A/ko
Application granted granted Critical
Publication of KR102465067B1 publication Critical patent/KR102465067B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
KR1020207026571A 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템 Active KR102465067B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227002190A KR102494449B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631,304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720,525 2018-08-21
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002190A Division KR102494449B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템

Publications (2)

Publication Number Publication Date
KR20200121342A KR20200121342A (ko) 2020-10-23
KR102465067B1 true KR102465067B1 (ko) 2022-11-10

Family

ID=65995829

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207026571A Active KR102465067B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템
KR1020227002190A Active KR102494449B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템
KR1020237003098A Active KR102684890B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227002190A Active KR102494449B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템
KR1020237003098A Active KR102684890B1 (ko) 2018-02-15 2019-02-15 진핵 게놈 변형을 위한 조작된 cas9 시스템

Country Status (11)

Country Link
US (2) US10767193B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752607A1 (cg-RX-API-DMAC7.html)
JP (3) JP7109547B2 (cg-RX-API-DMAC7.html)
KR (3) KR102465067B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902536B (cg-RX-API-DMAC7.html)
AU (3) AU2019222568B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020010479A2 (cg-RX-API-DMAC7.html)
CA (2) CA3281020A1 (cg-RX-API-DMAC7.html)
IL (2) IL321024A (cg-RX-API-DMAC7.html)
SG (1) SG11202007382TA (cg-RX-API-DMAC7.html)
WO (1) WO2019161290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
SG11202108812SA (en) 2019-02-15 2021-09-29 Sigma Aldrich Co Llc Crispr/cas fusion proteins and systems
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
JP7785002B2 (ja) 2019-11-05 2025-12-12 ペアーワイズ プランツ サービシズ, インコーポレイテッド 対立遺伝子のrnaにコードされたdnaの置換のための組成物および方法
KR20220116512A (ko) 2019-12-17 2022-08-23 시그마-알드리치 컴퍼니., 엘엘씨 박테로이데스의 게놈편집
GB2617659B (en) * 2020-02-14 2024-05-01 Metagenomi Inc Enzymes with RuvC domains
CA3177051A1 (en) * 2020-03-31 2021-10-07 Metagenomi, Inc. Class ii, type ii crispr systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
KR102679001B1 (ko) * 2020-09-21 2024-06-28 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
AU2021374974A1 (en) * 2020-11-06 2023-05-25 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法
EP4592322A4 (en) * 2022-09-23 2026-08-05 Chuang Woei Jer Fusion protein targeting alpha(IIB)beta3 integrin and containing a tissue plasminogen activator or a variant thereof, and its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170314015A1 (en) 2014-03-26 2017-11-02 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
KR102955556B1 (ko) * 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
EP3097212A4 (en) * 2014-01-24 2017-10-04 North Carolina State University Methods and compositions for sequences guiding cas9 targeting
US10450584B2 (en) * 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3845655B1 (en) * 2014-10-01 2025-01-01 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
DK3604527T3 (da) 2016-06-02 2021-05-31 Sigma Aldrich Co Llc Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
CN109688820B (zh) 2016-06-24 2023-01-10 科罗拉多州立大学董事会(法人团体) 用于生成条形码化组合文库的方法
EP4650364A3 (en) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11242513B2 (en) * 2016-12-14 2022-02-08 Wageningen Universiteit Thermostable Cas9 nucleases
KR102655021B1 (ko) * 2017-07-11 2024-04-04 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
CA3071769A1 (en) 2017-07-31 2019-02-07 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170314015A1 (en) 2014-03-26 2017-11-02 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
비특허1
비특허2

Also Published As

Publication number Publication date
AU2019222568B2 (en) 2021-10-14
AU2022200130A1 (en) 2022-02-10
EP3752607A1 (en) 2020-12-23
WO2019161290A1 (en) 2019-08-22
JP2024161376A (ja) 2024-11-19
KR20220015502A (ko) 2022-02-08
IL274528B2 (en) 2025-10-01
CA3084020A1 (en) 2019-08-22
JP7559005B2 (ja) 2024-10-01
IL274528B1 (en) 2025-06-01
US20200354752A1 (en) 2020-11-12
KR20200121342A (ko) 2020-10-23
JP2021505180A (ja) 2021-02-18
KR102684890B1 (ko) 2024-07-12
JP7109547B2 (ja) 2022-07-29
CA3084020C (en) 2025-11-25
JP2022122910A (ja) 2022-08-23
KR20230022258A (ko) 2023-02-14
SG11202007382TA (en) 2020-08-28
IL321024A (en) 2025-07-01
CN111902536A (zh) 2020-11-06
AU2024202158A1 (en) 2024-05-02
IL274528A (en) 2020-06-30
KR102494449B1 (ko) 2023-01-31
US20190249200A1 (en) 2019-08-15
AU2019222568A1 (en) 2020-05-21
AU2024202158B2 (en) 2026-07-30
CN111902536B (zh) 2024-07-30
US10767193B2 (en) 2020-09-08
US12297449B2 (en) 2025-05-13
AU2022200130B2 (en) 2024-03-07
CA3281020A1 (en) 2026-03-02
BR112020010479A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
AU2022200130B2 (en) Engineered Cas9 systems for eukaryotic genome modification
KR102458395B1 (ko) 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선
KR20240046316A (ko) 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
AU2020221274B2 (en) Crispr/Cas fusion proteins and systems
CN113631700B (zh) 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
BR122025004697B1 (pt) Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão
BR122025004697A2 (pt) Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000